Patents Assigned to IMPACT THERAPEUTICS (SHANGHAI), INC
  • Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
    Patent number: 11547703
    Abstract: The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A3, B1-B3, D1-D4 and R1-R2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: January 10, 2023
    Assignee: IMPACT THERAPEUTICS (SHANGHAI), INC
    Inventors: Suixiong Cai, Ye Edward Tian, Xiaozhu Wang
  • SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20220259211
    Abstract: A compound of formula I, or a stereoisomer, tautomer, N-oxide, hydrate, isotope-substituted derivative, or solvate thereof, or a pharmacologically acceptable salt thereof, or a mixture thereof, of a prodrug thereof. The compound of formula I is a kinase inhibitor which can be used for treating clinical disorder caused by DDR deficiencies, such as cancers.
    Type: Application
    Filed: July 8, 2020
    Publication date: August 18, 2022
    Applicant: IMPACT THERAPEUTICS (SHANGHAI), INC
    Inventors: Sui Xiong CAI, Ye Edward TIAN, Xiaozhu WANG
  • Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
    Patent number: 11345710
    Abstract: Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: May 31, 2022
    Assignee: IMPACT THERAPEUTICS (SHANGHAI), INC
    Inventors: Suixiong Cai, Ye Edward Tian, Zhiqiang Dong, Xiaozhu Wang
  • 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
    Patent number: 11345711
    Abstract: Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: May 31, 2022
    Assignee: IMPACT THERAPEUTICS (SHANGHAI), INC
    Inventors: Sui Xiong Cai, Ye Edward Tian